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Objectives. To examine if informing people in free-at-the-point-of-usemedical systems
of the financial value of medicines, and priming them with the fact that the medication is
funded by taxation, influences people’s perceived value and efficacy of the medicines,
feelings of burdensomeness and guilt, and intended adherence.
Design. An experiment was implemented to examine the impact of medication labelling
featuring the presence (vs. absence) of the phrase ‘funded by UK the taxpayer’ and pricing
information (absent vs. £20 vs. £200) on outcome measures.
Methods. A total of 257 UK participants (age: M = 29.10 years, SD = 9.15; 89 males,
167 females, one undisclosed)whowere currently takingmedicationwere recruited from
an online participant pool (prolific academic). Participants viewed an image of a
medication with the manipulated price and taxation message on the label. They then
completed a number of measures to gauge perceived value and efficacy of the medicines,
feelings of burdensomeness and guilt, and intended adherence.
Results. Findings point to both positive and negative consequences of such labelling of
medication, with the taxpayer label increasing perceptions of value but also increasing
feelings of guilt. The price labels demonstrated a positive effect on perceived value and
intended adherence.
Conclusions. Discussion of results is centred on potential policy implications, applied
recommendations, and future directions for study.
Statement of contribution
What is already known on this subject?
 Health care services must balance the provision of medicines and services with the task of remaining
economically viable.
 Altering medication labels and packaging can produce beneficial effects on compliance, improving
population health while also reducing waste.
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What does this study add?
 An examination of a previously suggested (but untested) alteration tomedication labelling. Specifically,
the study examines the influence of including pricing information and the phrase ‘funded by the UK
taxpayer’ on medication labels.
 The disclosure of pricing information led to greater intentions to adhere to the medication schedule
and greater perceptions of the medicine’s value.
 The inclusion of the taxpayer information increased perceived value, but also increased self-reported
feelings of guilt.
 Overall, we provide new insight into a potential approach thatmight be utilized to improvemedication
use, but also acknowledge potential negative emotional repercussions.
Background
Health care providers face the challenge of balancing the provision of services and
medications with the need to remain economically viable. To this end, a range of
approaches leveraging insights from behavioural science have been proffered to help
identify and intervene where money could be saved, or service efficacy improved. One
area that has shown promise is altering medication packaging. As an example, pill boxes
and blister packaging featuring a reminder of what day of the week to take certain
medications have been shown to benefit compliance (Conn et al., 2015). Yet, other
approaches focussing on alterations to medication packaging have been suggested, but
remain largely untested. In 2015, for example, the UK health minister proposed that
medications costing more than £20 could feature the cost of the medication and include
thewords ‘funded by theUK taxpayer’ (Hunt, 2015). The healthminister argued inclusion
of such information would have several benefits, including limiting the waste of
medication and improving patient care by boosting adherence to drug regimes. In
response, PharmacyVoice (an association representing the views of pharmacies)
suggested the move might not have the desired effects and may even backfire with
unintended consequences. Such consequences included the potential for feelings of
burden and guilt, misperceptions of drug efficacy based on price of the medication, and
people (particularly the elderly) being deterred from taking the medication as they may
feel worried about the impact on public funds. Some evidence for this was provided by a
qualitative study ofWelsh respondents, inwhich guilt emerged as a theme from a series of
focus groups (Yemm, Jones, & Mitoko, 2017). While the labelling scheme was never
implemented, its proposal does raise interesting and largely unexplored questions
regarding whether providing price information and including the phrase ‘funded by the
UK taxpayer’ on medicine labels might have either (or both) positive or negative
repercussions.
Disclosure of information – implications for perceived value, effectiveness, and
adherence to medication regime
The inclusion of pricing information and the funding phrase on medicines represents an
approach often classified as ‘disclosure of information’. The provision of certain
information to the public (sometimes referred to as ‘targeted transparency’) is one tool
governments can use to attempt to achieve a desired end. In 2010, for example, the US
Affordable Care Act required calorie information to be posted on menus in restaurants,
with an aim tomitigate the obesity crisis (Weil, Graham,& Fung, 2013). At first blush, such
efforts may seem laudable. Yet, evidence from the behavioural sciences suggest reactions
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to information disclosure may not be universally positive and in some cases may be
ineffective, or even backfirewith unintended consequences (e.g., Loewenstein, Sunstein,
&Golman, 2014). As an illustrative example, the use of healthwarnings aimed at deterring
certain harmful behaviours may employ fear appeals (e.g., disclosing the health risks of
smoking with graphic images) to attempt to curb the behaviour. However, this may
actually impede people from thinking about and hence become less likely to respond to,
the risks involved in the behaviour (e.g., Loeber et al., 2011). Of pertinence to the current
research, an independent study conducted by the Department of Health examining the
impact of disclosing price information on medication found ‘older people in need of
effective treatment could be deterred from taking the medicines they need because they
are worried about the impact on the public purse’ (see, Department of Health and Social
Care, 2012, pg. 321). The inclusion of pricing information was also advised against by the
Royal Pharmaceutical Society (RPS; Royal Pharmaceutical Society, 2016). The society
highlighted concerns that inexpensivemedicines could be regarded as a ‘cheap option’ or
sub-standard, and that patients with similar conditions might compare medications and
feel undervalued if found to be receiving the cheaper treatment. Indeed, research suggests
consumers believe and, therefore, judge lower-priced items to be of lower quality (see,
e.g., Gerstner, 1985; Huber & McCann, 1982; Rao & Monroe, 1989). Further, studies
suggest this ‘low price – low quality’ heuristic might have negative consequences for
actual efficacy – a link thought to be related to placebo effects. For example, consumers
who paid a discounted price for a product (e.g., an energy drink thought to increase
mental acuity) derived less actual benefit from consuming the product (e.g., they were
able to solve fewer puzzles) compared to those paying the regular price (Shiv, Carmon, &
Ariely, 2005). While the robustness of placebo effects, particularly in health domains
where it has been tested on a diverse array of diseases with heterogeneous results, is still
subject of debate (see, e.g., Hamberger, Meissner, Hinterberger, Loew, & Weimer, 2019;
Price, Finniss, & Benedetti, 2008), the possibility remains for negative consequences if
lower prices lead to less actual benefit from the medication.
Concern for certain groups (e.g., the elderly) to feel like a burden on the National
Health Service (NHS) was also raised by the RPS. As previously mentioned, responses to
the proposed scheme were probed in a qualitative study conducted in Wales via a focus
group approach. The study indicated findings consistent with the criticisms raised by the
professional bodies – suggesting that introducing cost to labels may make patients feel
guilty or unworthy, rather than encouraging them to use their medicines appropriately,
and that this effect may be more pronounced among the elderly (Yemm et al., 2017).
While certain groups, such as the elderly, may be influenced by the disclosure of
information pertaining to the price of medicine in heterogeneous ways, some theories
suggest disclosure of price may also have a more uniform effect – arguing cost acts as one
way to communicate the value of a product. In particular, early theories and more recent
research suggest that cost of a product may act as a signal of quality (e.g., Milgrom &
Roberts, 1986; Spence, 1974; Veblen, 1899). Others argue higher price alone is not
sufficient to signal higher quality, and instead, that higher prices should be accompanied
by other signals of quality, for example word of mouth reviews (Alpert, Wilson, & Elliott,
1993). Regardless of the competing claims, the potential influence of pricing information
on perceived value and efficacy may impact adherence to medical regiment. This is
important as recent reports suggest patients may not adhere to their medicine regime as
1Note that the details available online in terms of this study’s design, participants, findings, etc., are very sparse.
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much as 50% of the time, with substantial implications for the health of the population
(e.g., Brown et al., 2016). Further, this lack of adherence generates medical waste with
negative environmental and financial ramifications (e.g., Castensson & Ekedahl, 2010;
McKeown & Pawloski, 2013). As such, finding ways to improve adherence is imperative.
Drawing on the price-quality heuristic and targeted transparency, disclosing the price of
medication may be beneficial to patients in situations where price signals the medication
to be valuable and effective. To this end, such a signal may have downstream effects for
medication adherence, improved population health, economic sustainability, and waste
reduction.
In summary, while research has broadly noted that disclosure of information has the
potential to be advantageous, it also can be ineffective or even backfire for a number of
reasons tethered to psychological shortcomings and biases, for example lack of attention,
motivated attention, social pressure (see Loewenstein et al., 2014, for a review). Further,
little has been done to specifically consider the affective and cognitive consequences of
disclosing price and source of funding on medical products.
Psychological reactions to explicit reminders of socialized health care – a social
exchange perspective
While the literature on the influence of actual taxation on health-related behaviours is
relativelywell developed (see e.g.,Wright, Smith,&Hellowell, 2017, for a review), there is
little to inform how explicitly stating amedical product is paid for by taxpayers influences
attitudes and behaviours.While the vaguely referenced ‘independent study’ referred to by
the Department of Health reported ‘concerns’ older people may have about taking from
public funds, it does not inform other potential psychological reactions.
In the UK, as inmany EU countries, medical service transactions aremostly offered in a
free-at-point-of-use context. As such, one theory well-positioned to inform psychological
reactions to this service is social exchange theory (see e.g., Cropanzano &Mitchell, 2005,
for a review). The theory posits that people respond to receiving goods (broadly defined as
including services, products, gifts, favours) as a social transaction. Consequently, a
consideration of the literature on social exchange, gift-giving, reciprocity, and the
exchange of goods from a social psychological perspective more generally is warranted.
This literature is also appropriate as the UK health minister specifically suggested that the
inclusion of the phrase ‘funded by the UK taxpayer’ on medication labelling would make
salient the ‘social contract’ between the National Healthcare Service and the public –
again, signalling the notion that the provision of medication is an exchange of sorts.
The social exchange literature often focuses on the idea of a ‘social contract’ and
identifies several ways people can respond to receiving a good or service. One possibility
is that a social exchange instils the psychological state of indebtedness – a feeling similar to
gratitude, albeit entailing a sense of obligation to repay one’s debts towards the
benefactor. In comparison to gratitude, indebtedness is considered to have undesirable
qualities that people generally try to avoid (e.g., Fredrickson, 2004). Tethered to (but
distinct from) the psychological state of indebtedness are feelings of guilt at having
received something, for example research finds patients receiving the ‘gift’ of an organ
donation reported elevated feelings of guilt after surgery (Fukunishi et al., 2001).
Relatedly, receiving help from others (e.g., health care providers) can lead to feelings of
burdensomeness – a mental state characterized by the belief that the person is a drain on
others, and that others would ‘be better off if I were gone’. As such, feelings of guilt and
burdensomeness have important implications for psychologicalwell-being (e.g., Bernabé-
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Valero, Moret-Tatay, & Navarro-Sancho, 2018). Among older adults, burdensomeness has
been found to be associatedwith suicidal ideation (e.g., VanOrdern, Cukrowicz,Witte, &
Joiner, 2012). Despite the negative valence of these responses to a social exchange, prior
theory and research suggest such feelings may help promote healthy behaviours and
attitudes. Connecting the present study to social exchange theory and the potential for
feelings of guilt and indebtedness – following the receipt of a ‘gifted’ medication, oneway
to clear these feelings is to indicate increased value of the good (the medicine). This may
be particularly likely when the source of the good is made salient (i.e., when a person is
reminded the medication is funded by their fellow citizens). Indeed, prior research aligns
with this. As just one example, Achille, Ouellette, Fournier, Vachon, and Hébert (2006)
found that peoplewhohad received an organ donation reported greater indebtedness and
also reported greatermedication adherence, perhaps because they valued themedication
more as a way to psychologically ‘pay off’ feelings of indebtedness. Thus, it is not only
economic and efficacy concerns that may be aroused by the presence of pricing
information and the presence of the ‘funded by the UK taxpayer’ phrase on medication
labelling – theremay also be important psychological consequenceswith implications for
behaviour.
The present research
Given the need to identify potential interventions to help health care providers save
money and improve services, we probe the suggestions put forward by the 2015 UK
health minister to alter medication labels. Specifically, these novel suggestions recom-
mended altering labels to include pricing information and the phrase ‘funded by the UK
taxpayer’. Given the literature on disclosure of information and the lack of empirical
evidence concerning potential positive and negative outcomes in this context, we sought
to experimentally examine the implications of viewing a medication label featuring
pricing information (absent vs. £20 vs. £200) and the phrase ‘funded by the UK taxpayer’
(present vs. absent) on perceived value, efficacy, and intentions to adherence to
medication regimen. In addition, based on prior work from social exchange theory
indicating a range of responses to receiving goods, we examined how these labels might
influence feelings of burdensomeness and guilt.
Hypotheses
Two broad a priori hypotheses were posited. First, based on the literature on information
disclosure and extant work on the price-quality heuristic (the economic tenant that the
presence of a price, and higher prices, signal greater quality), we predicted:
1. Labels featuring pricing information and higher prices (vs. the absence of price
information) would lead to the medication being perceived as greater in value, more
effective, and result in heightened intentions to complete the full course of
medication.
Secondly, based on the literature on information disclosure and social exchange
theory, we predicted:
2. A main effect such that the presence of the text ‘funded by the UK taxpayer’ would
lead to greater feelings of burdensomeness and guilt. It was also predicted that the
presence of the phrase would lead to the medicine being seen as more valuable as it
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makes salient to the participant that the funders are their fellow citizens, and should
be valued accordingly.
No a priori hypotheseswere posited concerning the interaction of pricing information
and the ‘funded by the UK taxpayer’ phrase.
Method
Participants
Sample size was determined via an a priori power analysis given the 2 × 3 between-
subjects ANOVA we planned to pursue, using a medium effect size (f = .25), and power
set to .80 (conducted via G*Power; Faul, Erdfelder, Buchner, & Lang, 2009). This
suggested a total sample size of 213. The study aimed to exceed this amount to account for
attrition, potential low-quality data, and exclusion criteria. As such, two hundred ninety-
five UK participants over the age of 18 were recruited from Prolific Academic – a crowd-
sourced Internet workforce – in exchange for financial compensation (£1.50). A
recruitment filter was applied to recruit participants who were currently taking
medication. We opted to apply this filter as previous research indicates measures of
intention are more likely to translate to actual behaviour (and thus may help close the
‘intention-behaviour’ gap) when the question relates to the person’s self-identity versus a
hypothetical scenario unrelated to one’s current condition (see, e.g., Sheeran & Webb,
2016). After removing participants who appeared to rush or take a long time with the
study (≥ or ≤3 SDs from the mean completion time), and/or who did not complete the
primary dependant variable, and those who failed any of the data quality check questions
(these are explained in detail in the ‘materials and procedure’ section), there were two
hundred and fifty-seven participants remaining (age: M = 29.10, SD = 9.15, range =
18–43; 89males; 167 female, 1 undisclosed). The studywas listed on the recruitment site
as ‘exploring personality and attitudes’. The accompanying brief description stated the
study aimed to examine the relationship between personality traits and decisions. The
description also requested participants only take part if they were currently taking any
kind of medication. Participants were randomly assigned to conditions in a 2 (‘funded by




Tobolster the cover story, participants first completed a shortmeasure of personality (ten-
item personality index; Gosling, Rentfrow, & Swann, 2003). Example items include ‘I see
myself as extraverted, enthusiastic’ and ‘I see myself as conventional, uncreative’.
Responses were made using a scale anchored at 1 (Disagree strongly) and 7 (Agree
strongly). After completing this measure, participants were randomly assigned to view
one of the medication labels.
Medicine labels manipulation
Participants were then given the instructions ‘The following section is designed to assess
attitudes towards prescription drugs. Please imagine the doctor has prescribed you the
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medication on the next screen. Take a moment to look at the image and read over the
printed label. Once you have done this please answer the questions on the following
pages’. Participants then viewed an imageof somemedicine featuring oneof the six labels.
The medication displayed were pills in a standard translucent orange cylinder. At the
top of the label, it was indicated themedicationwas called ‘Radacet’. The namewas taken
from a medicine name generator website (see pills.olivervogel.net/). A fabricated
medicine name was used to avoid familiarity effects for extant drugs that people may be
aware of and therefore have some idea of their value, what they are used to treat, and their
efficacy. At the bottom of the label, information commonly seen on medications was
included. Specifically, the label noted: ‘Store at 10-20°C’, ‘KEEP OUT OF REACH OF
CHILDREN’, and ‘STORE IN A COOL DRY PLACE’. All font was presented in Arial, black,
and 15-point size. We opted to use this font as it is one of two core fonts employed by the
NHS for text communications (see NHS England, 2021). The centre of the label featured
the manipulated information, containing the pricing information (absent, £20, or £200),
and, either the presence or absence of the phrase ‘Funded by the UK taxpayer; please see
Supplementary Materials for an example image). The monetary values of £20 and £200
were selected based on two lines of reasoning. First, £20 was selected based on the
recommendation of the (then) health secretary’s suggestion to only include the pricing
information if themedication cost £20 or above. The higher value of £200was included as
it is 1,000%more than the £20 price tag. Second, at time of writing, these valuesmap onto
approximate US dollar values for some relatively commonmedications for example Advil
(branded Ibuprofen) can cost around $20, and Ritalin (a common medication for ADHD)
costs approximately $200. The following measures were then administered in a random
order to mitigate potential order effects.
Medication value
Perceived value of the medication was assessed via the item ‘This medicine is valuable’
assessed on a 10-point Likert type scale (1 – completely disagree, 10 – completely agree).
Medication effectiveness
Perceived effectivenesswas assessedwith a single item ‘Thismedicine is effective’ on a 10-
point Likert type scale (1 – completely disagree, 10 – completely agree).
Intended adherence to medication regime
Intentions to adhere to the medication plan were examined with the item ‘If I were
prescribed this medicine I would complete the full course of this medication’ assessed on
a 10-point Likert type scale (1 – completely disagree, 10 – completely agree).
Burden measure
Feelings of burden were assessed with the six-item perceived burdensomeness scale
(Peak et al., 2016). Instructions read ‘Think back to themedication you saw and complete
the items below’. Example items include ‘I think I am a burden on society’ and ‘I make
things worse for the people in my life’ assessed on a seven-point Likert type scale (1 – not
at all true for me, 7 – very true for me).
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Guilt measure
Feelings of guilt were assessed via the question ‘To what extent would you feel guilty if
you received the medication that you saw?’ with responses measured on a 10-point Likert
type scale (1 – not at all guilty, 10 – very guilty).
Demographics measures
These measures appeared after the above dependent variables and included sex, age,
ethnicity, nationality, religion/philosophy, political orientation, importance of political
orientation, political party affiliation, country of birth, country of residence, and
employment status.
Current medication use question
After demographicmeasures, participants indicated if theywere currently taking any kind
ofmedication (Yes/No). This questionwas used in conjunctionwith the recruitment filter
to check for participants whose medication regimen might have changed since they
initially indicated their medication use for screening purposes.
Data quality measures
In an effort to attain quality responses, we included three approaches aimed at bolstering
data integrity. First, as part of the burden measure, an additional ‘catch’ question was
included ‘I am paying attention to this study, to indicate that I am paying attention I will
select the number 6’. The second approach was to include probe questions as part of the
demographics section. The following three questions were included – First, an open-
ended question ‘In your own words, what was the purpose of the study?’ Second, ‘Have
you been in any other studies that were similar to this one? (Yes/No)’, then ‘If you
answered yes, please explain in the space below’. Finally, we also asked ‘Have you heard
about the proposed scheme to include price of mediation and the phrase ‘funded by the
UK taxpayer’ on medications?’ (Yes/No/Not sure). The final approach was another
question at the endof the study, but before the debriefing– ‘It is important that the datawe
receive from you represent a genuine quality response.Wewant to try to remove data that
is of low quality for example if the participant rushed, did not read instructions /
questions, or responded randomly to questions. Do you feel that you have read and
responded to every section of this study such that we can use your data? You will receive
payment regardless of whether you select yes or no.’ (Yes/No).
Analyses
Primary analyses
We submitted all measures to a 2 (funded by the UK taxpayer phrase: present vs.
absent) × 3 (price: absent vs. £20 vs. £200) between-subjects analysis of variance
(ANOVA).2 While we had no a priori hypotheses for interactions, we report the presence
or absence of them below in the interests of completeness (as exploratory analyses).
2 To account for the inflated experiment-wise type 1 error rate given the number of multiple comparisons, all pairwise t-test
reported are Bonferroni-corrected.We also ran these analyses as two one-way ANOVAs; this did not significantly alter patterns of
results.
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Results
Medication value
There was a main effect of the ‘funded by the UK taxpayer’ phrase, F(1, 251) = 5.66,
p = .018, η2p = .02, such that when the phrase was present (vs. absent) the medication
was seen are more valuable. A main effect of pricing information was also revealed, F(2,
251) = 8.83, p < .001, η2p = .07, such that there was no difference in valuation of the
medicine when comparing the £20 label to the no pricing label, t(173) = 1.48, p = .139,
d = .225, greater valuation when comparing the £200 to the £20 label, t(168) = 2.70,
p = .007, d = 4.16, and greater valuation when comparing the £200 to the no pricing
label, t(167) = 4.15,p < .001, d = .642.No interaction effect emerged, F(2, 251) = .594,
p = .553, η2p < .01 (see Figure 1).
Medication effectiveness
There was no main effect of the ‘funded by the UK taxpayer’ phrase, F(1, 251) = 007,
p = .935, η2p < .01. There was no main effect of pricing information, F(2, 251) = .342,
p = .711, η2p < .01. The analysis produced an interaction between the ‘funded by the UK
taxpayer’ phrase and pricing information, F(2, 251) = 4.72, p = .01, η2p = .04 (see
Figure 2; also, see Supplementary Materials for an unpacking of this interaction).
Adherence to medication regime
There was no main effect of the ‘funded by the UK taxpayer’ phrase, F(1, 251) = .275,
p = .600, η2p < .01. There was a main effect of pricing information, F(2, 251) = 3.98,
p = .020, η2p = .03 such that there was no difference in intentions to follow the
medication regime when comparing the £20 label to the no pricing label, t(173) = .339,
p = .734, d = .051, greater intention to follow the medication regime when comparing
the £200 label to the £20 label, t(168) = 2.27, p = .023, d = .350, and greater intention to






















Funded by the UK taxpayer
Absent
Funded by the UK taxpayer
Present
Figure 1. Influence of pricing information and ‘Funded by the UK taxpayer’ on medication value.
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(167) = 2.60, p = .009, d = .402. No interaction effect emerged, F(2, 251) = 1.01,
p = .367, η2p < .01 (see Figure 3).
Burden measure
There was no main effect of the ‘funded by the UK taxpayer’ phrase, F(1, 251) = .197,
p = .657, η2p < .01. There was also no effect of pricing information, F(2, 251) = 2.86,
p = .059, η2p = .02, and no interaction effect emerged, F(2, 251) = .580, p = .560,
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Funded by the UK taxpayer
Present
Figure 3. Influence of pricing information and ‘Funded by the UK taxpayer’ on adherence tomedication
plan.
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Guilt measure
There was a main effect of the ‘funded by the UK taxpayer’ phrase, F(1, 251) = 9.74,
p = .002, η2p = .04, such that when the phrase was present (vs. absent) people indicated
they would feel more guilty for taking the medicine. There was no main effect of pricing
information, F(2, 251) = 2.21, p = .112, η2p = .02. No interaction effect emerged, F(2,
251) = 1.39, p = .251, η2p = .01 (see Figure 5).
Summary
Results indicated that hypothesis 1 was partially supported – the inclusion of pricing
information led to the medicine being perceived as more valuable and led participants to
report greater intentions to complete the course of medication, with no effects emerging
on perceived efficacy of the medication. In terms of the UK taxpayer funded phrase,
hypothesis 2 was also partially supported – inclusion of the phrase resulted in the
medication being viewed as more valuable, but also increased feelings of guilt, with no
effects emerging on feelings of burden. See Table S1 for an overview of all means and SDs
for all dependentmeasures.3 See Table S2 for a correlationmatrix of keymeasures (across
conditions).
General discussion
The present research provides preliminary evidence that medication labelling disclosing
(vs. not) pricing information and including the phrase (vs. not) ‘funded by the UK
taxpayer’ impacts perceptions ofmedication value and intended adherence tomedication













Funded by the UK taxpayer
Absent
Funded by the UK taxpayer
Present
Figure 4. Influence of pricing information and ‘Funded by the UK taxpayer’ on burden.
3 Because of variations in prescription fees in the UK, we conducted an additional set of analyses included country of residence as a
control variable, following the same approach as outlined here. This did not meaningfully alter the pattern of results reported or
effect sizes.
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In terms of the pricing information, hypotheses were partially supported with effects
emerging on perceptions of the medications value. Specifically, the medication was seen
to bemore valuable when comparing the £200 price tag to the £20 label andwhen pricing
information was absent. Intentions to complete the course of medication were greater
when comparing the £200 price tag to the £20 label and the no pricing information
condition. Counter to our hypotheses, no effect of pricing information emerged on
perceived efficacy of the medication.
The inclusion of the phrase ‘funded by the UK taxpayer’ led participants to view the
medication as more valuable, as predicted. Similarly, feelings of guilt were greater when
the phrase was included on the medication; however, counter to our predictions, the
inclusion of the phrase did not produce greater levels of self-reported burdensomeness.
Implications for adherence for medical regimen
Taken together, the effects reported here constitute a ‘mixed bag’ with both potentially
positive and negative outcomes related to the UK’s former health minister’s proposal to
include pricing information and the ‘funded by the UK taxpayer’ phrase on medicines.
Such labelling alterations were originally put forward with the specific suggestion that it
would bolster adherence to medical regimens – boosting health while also reducing
medical waste and saving money. The data reported here provide partial support for this
claim. Of note, these data suggest such an effect on adherence is not likely to be driven by
the presence of the taxpayer funded phrase; rather, pricing information appears to be the
influential factor. More specifically, greater intentions to adhere to the medication
schedule only emerged when comparing the higher value (£200) against the lower price
(£20) and price absent conditions. This raises interesting questions concerning the
‘tipping point’ at which the cost of a medication leads to greater intentions to complete
the course of medication. If such a ‘sweet spot’ can be identified, this may suggest a
calibration of the recommendation for when pricing information would appear on
medicine labels such that itwould only appear once it breaches a certain pricing threshold















lt Funded by the UK taxpayer
Absent
Funded by the UK taxpayer
Present
Figure 5. Influence of pricing information and ‘Funded by the UK taxpayer’ on guilt.
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Continuing consideration of the intentions to adhere to themedication scheme driven
by the pricing information – it is interesting to note that therewas nomain effect of pricing
information on the perceived efficacy of the medication. This might suggest that greater
intentions to adhere to the medical regimen is not the result of greater perceptions of
efficacy engendered by a higher price (as might be suggested by ‘price-value’ approach).
However, it is possible the higher price label used in this study (£200) was not high
enough to instil perceptions that the medicine was a premium product. Future research
might attempt to replicate this study using greater price values to examine if the price-
efficacy link emerges when cost of the medicine exceeds the £200 upper level set in the
present research.
We also note that in these data, intentions to complete the course were high across
conditions. Such high responses might be driven by social desirability factors which may
be especially prevalent in health contexts (see, e.g., Sheeran&Orbell, 1996). There is also
a considerable literature illustrating the ‘intention-behaviour gap’, whereby intentions do
not always translate to behaviour (e.g., see Rhodes & Bruijn, 2013, for a meta-analysis in a
health context). Future research might attempt to examine whether the greater self-
reported intentions reported here, elicited by the pricing information, can make the leap
to impacting adherence to actual medication regimes in a more ecologically valid setting.
Potential unintended consequences – feelings of burdensomeness and guilt
PharmacyVoice’s suggestion that the labelling might backfire or have unintended
consequences also seems to have some support. Two broad objections to the label
changes were raised by the group. First, that people (especially the elderly) may feel a
sense of burdensomeness as a result of such labels, and second, misperceptions of drug
efficacy potentially being signalled by higher or lower prices. Concerning the latter, there
were no main effects for either the pricing information or taxpayer funded phrases on
perceived efficacy (however, as previously noted, thismay emergewith higher price tags.
Further, we did not examine price signals below the £20 threshold).
Concerning psychological reactions, there were no effects on self-reported burden-
someness in response to the pricing information or the funded by the UK taxpayer
manipulation. However, the inclusion of the ‘funded by the UK taxpayer’ phrase did elicit
greater levels of guilt, consistentwith social exchange theory. Specifically, guilt is thought
to emerge when agents perceive an unequal exchange and feel they have received more
from the transaction than they have given (e.g., Baumeister, Stillwell, &Heatherton, 1994;
Blau, 1968).
While feelings of guilt no doubt have a negative valence and potential implications for
well-being (e.g., Greenberg, 1980), some research suggests guilt can bolster medication
compliance (Achille et al., 2006). This raises difficult questions concerning the
appropriate routes government and policymakers can take to facilitate a desired
behaviour. While this debate is important, it is also outside of the focus of the current
research. However, we would like to highlight that this is the first study we are aware of
that examines the impact of this particular labelling approach on psychological reactions.
As such, we advise further study and better understanding of the boundary conditions,
moderators, and replicability of effects before putting such measures out ‘in the wild’.
Implications of labels disclosing price and funding 13
Recommendations, limitations, and future directions
Overall, when considering the inclusion of pricing information and the phrase ‘funded by
the UK taxpayer’, in the current data, there is no immediate evidence that including
pricing information leads to negative consequences on themeasures included (feelings of
guilt and burdensomeness). However, the inclusion of taxpayer phrase yielded greater
valuation of the medication, but also greater feelings of guilt. Given these results, one
might be tempted to make a recommendation to include pricing information – given no
negative effects emerged in the current study. However, we believe a more cautious
approach is warranted before such recommendations can be made. While greater
valuation may appear a useful consequence of the inclusion of pricing information, there
may be down sides too. That is, if medicine with a higher price point results in greater
perceived value, this might have implications for negative attitudes and behaviours
beyond the measures we included in the present study. For example, it is possible that
medications seen asmore valuable due to higher prices are not used properly for example
keeping/using them past the use-by date, inappropriately passing medications on to
someone with a similar health condition, or even reselling the medicine. Future studies
should probe the potential for these kinds of behaviours as a result of the inclusion of
pricing information and the subsequent greater valuation observed in our data. We also
believe future research examining how these interventions may produce heterogeneous
effects contingent on variations in, for example, personality, SES, nationality, and political
orientation arewarranted.Despite theplethora of futuredirections to be explored andour
suggestion for more thorough testing before potential implementation, the present
research represents a promising direction. Specifically, it demonstrates a low-cost means
by which we can pursue the improvement of health behaviours by simply changing the
messaging and information found on medication packaging.
Regarding other limitations, concerns were explicitly raised (e.g., by PharmacyVoice)
that negative consequences of such labelling may be particularly pronounced for older
people. However, in these data, greater levels of guilt emerged in a relatively young
sample. Despite this, the possibility remains that this effect may bemoremarked for older
people.We originally aimed to examine this possibility; however, we opted not to pursue
such analyses given the age range of our participants (18–43 years old).One reason for not
recruiting older people might relate to the ‘digital divide’, with significantly fewer older
people engagingwith computers and the Internet (e.g., Fox, 2004), and consequently the
method we used to collect data, that is an online survey. Future research might pursue
alternative recruitment techniques that yield greater participation by older populations,
thus allowing a test of whether those of advanced age respond differently to the
medication labelling.
Conclusion
The present research examined the influence of including pricing information and the
phrase ‘funded by the UK taxpayer’ on medication. We examined perceptions of value
and efficacy alongside intentions to complete the course of medication. In addition, we
probed the impact on feelings of burden and guilt. Findings point to both positive and
negative outcomes of such labelling, with data suggesting it may, for example, improve
adherence to medication, but also foster feelings of guilt. Ambiguities of the data were
discussed, andpotential policy recommendationswere considered. In sum, it is important
to consider novel means that enable health care providers to offer their services more
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effectively while also saving money. This particular approach may offer one tentative
route to achieve that end, albeit with some critical caveats.
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